Aastrom has brought together a group of highly skilled individuals from different areas of the industry creating a strong management team that is prepared to lead the Company through the clinical development stage and into the commercial marketplace. The Board of Directors is comprised of individuals with broad experience at both large public and private biotech and pharmaceutical companies, making them excellent representatives for Aastrom's shareholders and key advisors for the Company.
Board of Directors
Nelson M. Sims Chairman
Nelson M. Sims, Chairman since November 2007 and a Director since February 2006, most recently served as the President and Chief Executive Officer of Novavax, Inc., an international health and life science company. Prior to this, Mr. Sims held several senior executive management positions with Eli Lilly and Company until his retirement in 2001. During his 28 year tenure at Eli Lilly, Mr. Sims' positions included President of Eli Lilly Canada, Inc., Executive Director of Alliance Management, Vice President of Hybritech, Inc. and other assignments in sales and marketing management and business development. In his last position with Eli Lilly, Mr. Sims lead the Alliance Management initiative responsible for "Best in Class" partnering capabilities for research and development, commercial and development alliances. Mr. Sims received a Bachelor of Science degree in Pharmacy from Southwestern Oklahoma State University, and completed the Tuck Executive Program at the Amos Tuck School of Business at Dartmouth College. He also serves on the board of MDS, Inc.
George W. Dunbar Chief Executive Officer, President, Chief Financial Officer and Director
George W. Dunbar joined Aastrom as Chief Executive Officer, President, and a member of the Company's Board of Directors in July 2006. He has more than thirty years of experience in the healthcare field, including the biotech, pharmaceutical, diagnostic and device sectors. During this period, he has spent more than fifteen years as a chief executive officer of established and early-stage healthcare companies. From 2004 through 2005, he was the Chief Executive Officer of Quantum Dot Corporation. From 2003 through 2004 he was Chief Executive Officer of Targesome, Inc. and also served on the Business Advisory Board of Ulteria Capital Ltd. From 2001 through 2002, Mr. Dunbar was Chief Executive Office of Epic Therapeutics. Prior to 2001, he served at various times as Chief Executive Officer of Cytotherapeutics, Stem Cells, Inc. and Metra Biosystems, and in management positions with the Ares-Serono Group and Amersham International. Mr. Dunbar received a B.S. in Electrical Engineering and an MBA from Auburn University. Mr. Dunbar currently serves on the board of directors of Sonus Pharmaceuticals and Accuri Cytometers, Inc., as well as on the MBA Advisory Board of the Auburn University College of Business.
Timothy M. Mayleben, a Director since June 2005, most recently served as the President and Chief Operating Officer and a Director of NightHawk Radiology Holdings, Inc. Prior to this he was an advisor to life science and healthcare companies through his advisory and investment firm, ElMa Advisors. Mr. Mayleben was formerly the Chief Operating Officer of Esperion Therapeutics, now a division of Pfizer Global Research & Development. He joined Esperion in late 1998 as Chief Financial Officer. While at Esperion, Mr. Mayleben led the raising of more than $200 million in venture capital and institutional equity funding and later negotiated the acquisition of Esperion by Pfizer in December 2003. Prior to joining Esperion, Mr. Mayleben held various senior and executive management positions at Transom Technologies, Inc., now part of Electronic Data Systems, Inc., and Applied Intelligent Systems, Inc., which was acquired by Electro-Scientific Industries, Inc. in 1997. Mr. Mayleben holds a Masters of Business Administration, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a Bachelor of Business Administration degree from the University of Michigan Ross School of Business. He is on the Advisory Board for the Wolverine Venture Fund.
Mr. Mayleben is the Chairman of the Audit Committee, and also serves on the Compensation Committee of the Aastrom Board of Directors.
Alan L. Rubino, a Director since September 2005, is the President of Akrimax Pharmaceuticals, LLC. Prior to this he served as President and Chief Operating Officer of Pharmos Corporation. Mr. Rubino has continued to expand upon a highly successful and distinguished career that included Hoffmann-LaRoche, Inc. from 1977 to 2001, where he was a member of the U.S. Executive and Operating Committees and an SEC corporate officer. During his Roche tenure, he held a series of key executive positions in marketing, sales, business operations, supply chain and human resource management. Mr. Rubino also held senior executive positions at PDI, Inc. and Cardinal Health from 2001 to 2005. He received a Bachelor of Arts degree in economics from Rutgers University with a minor in biology/chemistry, and completed post-graduate educational programs at the University of Lausanne and Harvard Business School. Additionally, he serves on the Board of Rutgers University Business School.
Mr. Rubino is the Chairman of the Compensation Committee and also serves on the Audit Committee of the Aastrom Board of Directors.
Stephen G. Sudovar, a Director since July 2005, is currently CEO of SGS Associates, a healthcare management consulting firm. Before this Mr. Sudovar served as President and CEO of EluSys Therapeutics, Inc., a start-up biopharmaceutical company with a pipeline of products in various stages of development. Prior to joining EluSys in 1999, Mr. Sudovar was the President of Roche Laboratories, Inc., a division of Hoffmann LaRoche, Inc. Before he assumed the duties of President at Roche, Mr. Sudovar held the positions of Senior Vice President, Executive Director of Special Projects at Basel Headquarters (Switzerland), and Vice President and General Manager. Prior to joining Roche, Mr. Sudovar was the CEO and Chairman of Pracon Incorporated, a health care consulting and communications firm he founded and presided over for ten years. He is an adjunct professor of management at Montclair State University, and has published articles on a wide variety of issues related to the field of healthcare. Mr. Sudovar holds a Bachelor of Science degree in Marketing from St. Peter's College, and a Masters of Business Administration degree from Fairleigh Dickinson University.
Mr. Sudovar serves on the Audit and Corporate Governance & Nominating Committees of the Aastrom Board of Directors.
Susan L. Wyant, Pharm.D, a Director since June 2002, is the founder and President of The Dominion Group, a full service marketing research and consulting firm assisting major pharmaceutical as well as start-up biotechnology companies in making informed business decisions. Dr. Wyant leads her staff in design, implementation and analysis of customized qualitative and quantitative primary marketing research and business intelligence projects addressing all aspects of product development and marketing. Prior to founding The Dominion Group, Dr. Wyant held various marketing and management positions related to the pharmaceutical industry. In addition to her extensive work in pharmaceutical consulting and marketing, she is a Clinical Associate Professor at Medical College of Virginia School of Pharmacy and Shenandoah University School of Pharmacy. Dr. Wyant received a Bachelor of Science degree and a Doctor of Pharmacy degree from the Medical College of Virginia/VCU School of Pharmacy.
Dr. Wyant serves on the Compensation and Corporate Governance & Nominating Committees of the Aastrom Board of Directors.
Robert L. Zerbe, M.D., a Director since January 2006, is the Chief Executive Officer of QUATRx Pharmaceuticals Company, an Ann Arbor, MI-based, venture-backed drug development company co-founded by Dr. Zerbe in 2000. Prior to this, Dr. Zerbe held several senior executive management positions with major pharmaceutical companies including Eli Lilly and Pfizer (formerly Parke-Davis). During his tenure at Eli Lilly, Dr. Zerbe's clinical research and development positions included Managing Director, Lilly Research Center U.K., and Vice President of Clinical Investigation and Regulatory Affairs. He joined Pfizer in 1993, becoming Senior Vice President of Worldwide Clinical Research and Development. In this capacity he led the clinical development programs for a number of key products, including Lipitor® and Neurontin®. Dr. Zerbe received his M.D. from the Indiana University School of Medicine, and has completed post-doctoral work in internal medicine, endocrinology and neuroendocrinology at Indiana University and the National Institutes of Health. He also serves on the boards of A.P. Pharma, Inc. and Anesiva, Inc.
Dr. Zerbe is the Chair of the Corporate Governance & Nominating Committee of the Aastrom Board of Directors.
Print page |
Email page
